MC4R and obesity disorder: In addition to obesity therapies, the other potential use of MC4R agonists as therapeutics for erectile dysfunction and premenopausal hypoactivity sexual desire disorder has also been investigated, including melanotan II (University of Arizona) [225], bremelanotide (Palatin Inc) [226], and PF-00446687 (Pfizer Inc) [227].